CompletedNot Applicable

Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction

China230 participantsStarted 2019-07-01

Plain-language summary

The aim of this study is to evaluate the impact of concomitant main pancreatic duct exposure, repair, or reconstruction during minimally invasive pancreatic tumor enucleation on long-term patient prognosis and quality of life.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. age between 18 and 75 years, regardless of gender;
✓. patients with solitary benign or low-grade malignant pancreatic tumors, including NET, SPN, and cystic tumors;
✓. eligible for pancreatic parenchyma-sparing resection (PSR) according to contemporary guidelines;
✓. patients with an ECOG performance status of 0 or 1;
✓. successfully received MIEN (laparoscopic or robotic)

Exclusion criteria

✕. body mass index \> 35 kg/m2;
✕. concomitant malignancies;
✕. intraoperative frozen section or postoperative pathology indicating malignancy, requiring conversion to oncologic resection;
✕. loss to follow-up within 90 days postoperatively.

What they're measuring

Incidence of Clinically Relevant Postoperative Pancreatic Fistula

Timeframe: Within 90 days after surgery.

Trial details

NCT IDNCT06024343

SponsorFudan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-30

View on ClinicalTrials.gov More Pancreatic Tumor, Benign trials